MATERIALS AND METHODS
Monoclonal antibodies. Murine MoAb KMO1, AF6, BF2, B03, CE5, FD5, HH9, 1E3, and JG2 were developed in our laboratories using cancer cell lines as the immunogen (Ohyanagi et al. 1987 ; Kano et al. 1990a ). Anti-hepatitis B surface (HBs) antigen monoclonal antibody 2117 (IgM), the negative control antibody was also developed in our laboratories. Purification of these MoAbs was performed by precipitation with 50% ammonium sulfate and HPLC on a TSK G3000SW column (Toso, Tokyo). Antibody 19-9 used in this study was a component of HISTO CA19-9TM kit (The Green Cross Corp., Osaka). Antibody C-50 used was a component of CanAg, CA-50 immunohistochemistry kit (Stena Diagnostics, Gothenburg, Sweden). The immunogens and isotypes of these MoAbs were summarized in Table 1 .
Cell lines. Lung cancer cell lines (PC-1, PC-3, PC-9, PC-10), stomach cancer cell lines (MKN-28, MKN-45, KATO-III), renal cancer cell line (NRC-12), and bladder cancer cell line (NBT-2) were purchased from Immunological and Biological Laboratory, Takasaki. Esophagus cancer cell lines (TE-1, TE-2, TE-3, TE-4, :rE-5, TE-6, TE-7, TE-8, TE-9, TE-10, TE-11) were kindly provided by Dr. T. Nishihira (Tohoku University, Sendai). The cell line HEK was established in our laboratory from the specimens of the patient bearing biliary duct carcinoma. Colorectal cancer cell lines (COLO-201, COLO-320DM), breast cancer cell line (ZR75-1), ovarian cancer cell line (PA-1), laryngeal cancer cell line (HEp2), oral cancer cell line (KB) and pancreatic cancer cell lines (PANC-1, MIA-PaCa-2) were purchased from Dainihon Pharmaceutical Company, Osaka. All cancer cell lines were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal calf serum. Mouse myeloma and hybridomas were cultured in DMEM medium supplemented with 10% heat inactivated horse serum.
CELISA. Reactivity of MoAbs with cancer cell lines was determined by CELISA as previously described (Kano et al. 1990b ). In brief, cancer cell lines were cultured overnight in 96-well microplate and then fixed with 0.1% glutaraldehyde at room temperature for 10 min. After blocking with 1% BSA in PBS, MoAb solution was added and incubated at 37°C for 1 hr. After washing, horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin (IgA+IgG+IgM) (Zymed Ltd. Inc., San Francisco, CA, USA) was added and incubated at 37°C for 1 hr, followed by washing. Substrate solution was added and the peroxidase reaction was carried out at room temperature for 30 min. The reaction was stopped by adding 4N-H2SO4 and the absorbance at 492 nm was read on a Titertek Multiskan spectrophotometer (Flow Lab. Inc., McLean, CA, USA).
Hemagglutination inhibition. For the screening of KMOI-related antibodies, MoAbs were examined for their inhibitory effect on KMOITM RPHA (The Green Cross Corp., Osaka) in which KMO1 was coupled to SRBC according to the method of Uemura et al. (1986) . The spent medium of COLO-201 was used for the KMO1 antigen solution. Serial doubling dilutions of the MoAb solutions (11ag/ml) were prepared using the dilution buffer provided in KMOITM RPHA kit. Each dilution was mixed with an equal volume of KMO1 antigen solution and left at room temperature for 1 hr before the remaining KMO1 antigen was determined by KMOITM RPHA. The inhibitory titer of each antibody solution was expressed as the lowest dilution ratio at which hemagglutination was observed in RPHA.
Absorption by sugar determinant. The reactivity of MoAb with Lewisa and its related determinants was investigated by the absorption test using Synsorb immunoadsorbent (Chembiomed Ltd, Edmonton, Alberta, Canada). One milliliter of MoAb solution was incubated with 50 mg of Synsorb Lewis-A, Lewis-B, H (type I), or H (type II) at room temperature for 2 hr with continuous shaking. After removal of Synsorbs by centrifugation, the remaining MoAb was determined by CELISA.
Sialidase treatment. The glutaraldehyde-fixed COLD-201 cells in 96-well microplate were treated with 0.1,ug/ml of sialidase (Sigma Chemical Co., St. Louis, MO, USA) at 3T C for 1 hr. After incubation, the plate was washed and MoAb was added. The rest of the procedure was the same as that used in CELISA.
Preparation of ganglioside fraction. The gycolipid antigen was isolated according to a slight modification of the method of Magnani et al. (1982) . COLO-201 cells were homogenized in 3 volumes (v/v) of distilled water with a homogenizes on ice. Glycolipids in the homogenate were extracted with chloroform/methanol/water (4 : 8 : 3, v/v/v) for 30 min at room temperature and centrifuged at 1,500 rpm for 10 min. The pellets were rehomogenized in distilled water, extracted, and centrifuged as before. The supernatant solutions were combined and phase-separated in chloroform/methanol/water (1: 2 :1.4, v/ v/v). The lower phase was re-extracted with the addition of methanol and 10 mM KC1 solution. The combined upper phase was evaporated under a NZ stream. The residue was dissolved in 0.2 N NaOH and incubated for 2 hr at 37°C. After neutralization with 0.2 N HCl in methanol and evaporation, the dry residue was suspended in distilled water, dialyzed against cold distilled water, and lyophilized. The residue was dissolved in chloroform/ methanol (1:1) and filtered to remove insoluble materials from the crude ganglioside fraction.
TLC-immunostaining. TLC-immunostaining was performed by a modified method of Magnani et al. (1982) . Glycolipid were developed with chloroform/methanol/0.2% CaCl2 (60: 40: 9, v/v/v) on HPTLC plate (Silica Gel 60, Merk, Darmstadt, Germany). The dried plate was soaked in 0.4% polyisobutylmethacrylate in n-hexane for 1 min. After drying, the plate was soaked in PBS containing 1% BSA and 1% polyvinylpyrrolidone (immunostaining buffer) for 1 hr at room temperature. Monoclonal antibody was diluted with the immunostaining buffer and was incubated with the plate for 1 hr at room temperature. After washing out excess antibody with PBS, 0.5,uCi/ml of '25I-labeled F(ab')Z sheep anti-mouse Ig (40,uCi/,ug, Amersham Japan Co., Tokyo) in the immunostaining buffer was overlaid on the plate and incubated for 1 hr at room temperature. The plate was washed, dried, and exposed to XR-5 x-ray film (Eastman Kodak, Rochester, NY, USA) for 20 hr. Gangliosides were also detected with resorcinol (Svennerholm 1957) . Gangliosides GM1, GM2, GDla, GDIb, and GTIb were purchased from Funakoshi Pharmaceutical Company, Tokyo.
Detection of antigen in human serum. The serum of cancer patients was obtained from the First Department of Surgery, Kobe University School of Medicine. Normal human serum was collected from healthy donors. The antigen in serum sample was determined by RPHA reagent, in which each purified MoAb was coupled to SRBC according to the method of Uemura et al. (1986) . The specimen under examination was judged as positive, if a 2 well or greater difference in the endpoint of hemagglutination exists between MoAb-coated SRBC and control SRBC annexed to KM01 RPHA kit.
RESULTS
Selection of MoAbs. In Table 1 are presented data on the selection of MoAbs inhibiting hemagglutination of KMOITM RPHA. In the 14 fusions with spleen cells of mice immunized with various cancer cell lines, approximately 10,000 hybridomas were obtained and 91 of them secreted antibodies reactive to cancer cells used for the immunization of mice but not to normal fibroblast cells. These 91 MoAbs were tested for the hemagglutination inhibition of KMOITM RPHA, and 8 were found to be inhibitory.
Seven of them were obtained from the fusion with spleen cells immunized with HEK and one was from the fusion with spleen cells immunized with COLD-201. The results with MoAbs 19-9 and C-50, of which were considered to recognize antigens similar to KMO1 antigen, were also shown in Table 1 . Reactivity of MoAbs with cancer cell lines. The reactivity of MoAbs listed in Table 1 with various cancer cell lines was examined. As shown in Table 2 , MoAbs were divided into 4 groups on the basis of the reaction pattern with cancer cell lines : group 1, BF2 and 19-9, which reacted with PC-3, KATO-III, COLO-201 and HEK ; group 2, CE5 and 1E3, which reacted with TE-2 and TE-7 in addition to those cell lines detected by group 1 MoAbs ; group 3, KMO1, AF6, BG3, JG2 and C-50, which reacted with TE-1, TE-9 and TE-10 in addition to those cell lines detected by MoAbs of the former two groups ; group 4, FD5 and HH9, which reacted with MKN-45 in addition to all cell lines detected by MoAbs of the former three groups.
Biochemical studies. The reactivity of all MoAbs except for JG2 to COLO-201 cells was markedly diminished, when the cells were treated with sialidase (Fig.  1) . The absorption of MoAbs with Synsorb Lewis-A diminished the binding activity of AF6 and JG2 to COLO-201 cells (Fig. 2) . Other immunoadsorbents including Synsorb Lewis-B, H (type I) and H (type II) had no effects (data not shown). The reactivity of MoAbs with ganglioside antigens from COLD-201 cells was examined by TLC-immunostaining.
The major component of the ganglioside recognized by KMOI showed almost the same mobility as that recognized by 19-9, that is, between GDla and GM1. Antibody C-50 also recognized the same ganglioside, but the intensity of the immunostaining was far weaker than that of KMO1 (Fig. 3) . MoAbs selected as shown in Table 1 were divided into 3 groups based on their reactivity pattern with the ganglioside fraction (Fig. 4) . Serum detection. Table 3 shows the positive ratio of antigens in human showed different reactivity with cancer patients sera. KMO1 and B03 reacted with sera from the patients with bile duct, liver, stomach and colorectal carcinoma besides sera from pancreatic carcinoma patients. CE5 and 1E3 reacted preferentially with sera from pancreatic carcinoma patients. AF6 and JG2 showed broad reactivity spectra including normal human sera.
DISCUSSION
We have recently developed a MoAb designated KMO1, which detects serum antigens for pancreatic carcinoma and other several gastrointestinal carcinomas (Ohyanagi et al. 1987 ). We also have been developing new MoAbs useful for the diagnosis and therapy of cancer (Ohyanagi et al. 1988 ; Kano et al. 1990a ), some of which were found to be cross-reactive with KMO1. They were divided into three groups depending on their reactivity with glycolipid antigens isolated from COLO-201. The reactivity of MoAbs with sera of cancer patients appeared to be correlated to that with the glycolipid antigens. MoAbs in group I, represented by 19-9, had a weak inhibitory activity toward the binding of KMOI to KMO1 antigen. Each MoAb in group II, represented by KMO1, showed almost the same inhibitory activity as KMO1. MoAbs in group III had the same inhibitory activity as group II. The glycolipid antigen of group I migrates between GDIa and GM1. This glycolipid is thought to be lacto-N-fucopentaose II as reported by Magnani et al. (1982) . MoAbs in groups II and III detected slowly migrating glycolipids in addition to the antigen detected by group I. This suggests that the antigenic determinants for groups II and III have longer sugar chains than that for group I. The weaker ability of group I to inhibit the binding of KMO1 to KMO1 antigen as compared with that of groups II and III shows the importance of the long-chain structure as the determinant of KMO1. The terminal structure of the KMOI antigen is assumed to be sialylated Lewisa, which is composed of a type 1 chain (Kano et al. 1990b) . It is reported that the type 1 chain is not elongated by itself and that, in the case of long-chain glycolipids, the determinants are carried by type 2 chain (Kannagi et al. 1985) . Such a case may occur antigen. From the results of inhibition studies using oligosaccharides, they showed that NS 19-9 was directed toward a fucose-containing terminal structure, while MSW 113 was directed toward a sialic acid-containg terminal structure. From the result of the reactivity with cancer cell lines, MoAbs were divided into 4 groups. It appeared that MoAbs of groups 1 and 2 corresponded to group I, and MoAbs of groups 3 and 4 coresponded to groups II and III. This result is thought to reflect both the expression level of the antigen in each cancer cell line and the avidity of each MoAb to the antigen. MoAbs of groups 1 and 2 recognized the same antigen, but the avidity of group 2 MoAbs may be stronger than that of group 1 MoAbs. The avidity of group 4 may be stronger than all other MoAbs in groups II and III. The reason for the poor reactivity of BF2 to cancer cell lines remains to be solved, but it may partly because of the poor reactivity of the peroxidase-conjugated anti-mouse immunoglobulin with IgA subclass. In those cancer cell lines with which groups 1 and 2 MoAbs reacted, PC-3, KATO-III, COLO-201, HEK, TE-2 and TE-7, the expression level of KMO1-specific longchain sialylated Lewisa might be very low when compared with that of sialylated Lewisa. On the other hand, in cancer cell lines TE-1, TE-9, TE-10 and MKN-45, significant amounts of long-chain carbohydrate may be expressed. These cancer cell lines may be the better source than COLO-201 to analyze the long-chain structure of KMO1 antigen. MoAbs obtained here will be useful for this purpose. The investigation of the sandwich immunoassay using these MoAbs in combination with KMO 1 is of another interest. Mansson et al. (1985) have found that MoAb C-50 could react with both sialylated Lewisa and its defucosylated derivative. In this study, we showed that MoAb C-50 has strong inhibitory activity toward the binding of KMO1 to KMO1 antigen and reacts with the same antigens, which are thought to be sialylated Lewisa and its long-chain derivative, as those detected by KMO1. Mansson et al. (1985) have also reported that C-50 could react with octasaccharide fraction of the monosialoganglioside in addition to hexasaccharide fraction, which corresponded to sialylated Lewisa. Holmgren et al. (1984) have shown the broad reactivity of C-5O with sera of patients with different carcinomas including hepatocellular carcinoma when compared with that of 19-9 antibody. These results suggest the close relationship between C-50 and KMO1. Further studies are needed to identify the structual differences of the antigens recognized by these two MoAbs.
